• Major Australian grain grower expands Axioma Biologicals adoption
• Program successfully transitioned from trials to large-scale commercial use
• Positive yield responses in most paddocks, especially wheat
• Global biostimulants market estimated at US$4-5 billion
• RLF plans to replicate model with other growers and evaluate local manufacturing

RLF AgTech Ltd has achieved a significant commercial milestone for its Axioma Biologicals range, following a successful three-year development program with a major Australian corporate grain grower. The program transitioned from initial field trials to large-scale commercial deployment across cereal and canola production, demonstrating positive yield responses in most paddocks, particularly in wheat. This success validates RLF's staged commercialization strategy and provides a repeatable framework for future adoption with other growers. The global biostimulants market, estimated at approximately US$4-5 billion, is expected to grow as biological crop inputs become more integrated with conventional farming systems.

RLF plans to expand the adoption of Axioma Biologicals by applying the same commercial development model with additional corporate growers across Australia and evaluating local manufacturing opportunities.